Laboratoire HRA Pharma to Acquire Mederma Brand From Merz Pharmaceuticals
May 07, 2019
Dechert is advising Laboratoire HRA Pharma, a portfolio company jointly backed by European private equity group Astorg Partners and Goldman Sachs Merchant Banking Division, on its planned acquisition of the global
rights to the Mederma brand from Merz Pharmaceuticals GmbH. The deal is expected to close in Q2 2019.
HRA Pharma is a fast-growing, innovative global consumer healthcare company. Mederma is a market leader in scar care and offers a range of over-the-counter products across the scar care, stretch marks and skin care categories.
Dechert advised Laboratoire HRA Pharma previously on the Compeed acquisition from Johnson & Johnson in 2017. The Dechert team on this most recent transaction included a London-based team led by partner Ross Allardice, with senior associate Tony Brown and associates Daniel Mansfield and David Nicholls, a Paris-based team led by partners Alain Decombe and Melanie Thill-Tayara and national partners Laurence Bary and Marie Fillon with associate Louis de Chezelles, a Munich-based team led by partner Giovanni Russo and National Partner Dr. Karl von Rumohr and a Washington-based team led by partner Craig Falls and counsel Beverly Ang.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
